GSK plc Shares Encouraging Results on Combined RSV and Shingles Vaccines
GSK plc (LSE/NYSE: GSK) has just announced encouraging topline findings from an important phase 3 trial involving adults aged 50 and older. This study assessed the immunogenicity, reactogenicity, and safety of AREXVY, a vaccine for respiratory syncytial virus (RSV), when given together with SHINGRIX, which is a recombinant zoster vaccine. Both vaccines utilize GSK's advanced AS01 adjuvants. The results were impressive and were delivered during a special session at a prominent European medical conference.
Insights from the Phase 3 Trial
The results suggest that administering AREXVY and SHINGRIX together produces an immune response similar to when the vaccines are taken separately. Importantly, the study showed that participants tolerated this combined vaccination approach well, with acceptable profiles for safety and reactogenicity. The most frequently reported side effects included pain at the injection site, fatigue, and myalgia, and the duration of these symptoms was similar in both vaccination scenarios.
Expert Opinion
Dr. Len Friedland, Vice President of Scientific Affairs and Public Health at GSK, shared his enthusiasm about these outcomes. He highlighted the broader societal benefits of enhancing adult immunization rates, noting the unfortunate reality that many adults miss critical vaccinations due to low uptake. GSK's co-administration strategy could ease the strain on healthcare systems by reducing the number of required visits for vaccinations.
Regulatory Path and Safety Aspects
In the aftermath of this trial, GSK intends to submit the findings for peer-reviewed publication and will utilize the data in regulatory submissions to agencies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These results hold substantial implications for public health, particularly since both RSV and shingles represent serious health threats for older adults, especially as age-related declines in immune function increase vulnerability.
Understanding the Risks of RSV and Shingles
RSV is a significant health risk for older adults, leading to high hospitalization rates each year. In the US, approximately 177,000 seniors are hospitalized due to RSV annually, and there is a concerning number of fatalities associated with it. Shingles, on the other hand, results from the varicella-zoster virus—which also causes chickenpox—and leads to painful rashes that can impact quality of life long after the initial outbreak.
A Deep Dive into AREXVY
AREXVY aims to prevent lower respiratory tract disease caused by RSV and has already received endorsements in over 50 countries. The vaccine contains the recombinant glycoprotein F of RSV in its prefusion state along with a proprietary adjuvant, AS01E. Efforts are ongoing in various regions to expand its availability to more vulnerable populations, particularly those aged 50 to 59 who are at an elevated risk.
AREXVY’s Indications
AREXVY is intended for active immunization to prevent lower respiratory tract disease caused by RSV in two key groups:
- Individuals aged 60 and older.
- Individuals aged 50 to 59 who are at higher risk for developing RSV-induced lower respiratory tract disease.
Overview of SHINGRIX
SHINGRIX is a non-live, recombinant vaccine that protects against shingles in individuals aged 50 and older. It features glycoprotein E, working in combination with the AS01B adjuvant system. Significantly, SHINGRIX offers protection against the natural decline in immune response that typically occurs with aging and is recommended for immunocompromised individuals who face a greater risk.
Indications for SHINGRIX
SHINGRIX is approved for use among:
- Adults aged 50 and older.
- Adults age 18 and older who are at risk for shingles due to known immunocompromising conditions.
The potential of both vaccines—AREXVY and SHINGRIX—is substantial in addressing major health risks faced by older adults. GSK remains dedicated to advancing healthcare solutions through continuous development and innovative research.
Frequently Asked Questions
What was the main finding of the GSK trial?
The main finding was that co-administering AREXVY and SHINGRIX resulted in a comparable immune response to administering them separately, with good tolerability.
How many adults participated in the trial?
A total of 530 adults aged 50 and older took part in the phase 3 trial.
What side effects were reported from the vaccines?
Commonly reported side effects included pain at the injection site, fatigue, and myalgia, with similar rates for both administration methods.
What is the significance of this trial?
This trial is significant because it explores a combined immunization approach, which could potentially lessen the need for multiple healthcare visits for older adults.
Where will the results be published?
The findings are anticipated to be submitted for peer-reviewed publication to reach a broader medical audience and aid regulatory efforts.
